Thoms W W, Eifel P J, Smith T L, Morris M, Delclos L, Wharton J T, Oswald M J
Division of Radiotherapy, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
Int J Radiat Oncol Biol Phys. 1992;23(3):491-9. doi: 10.1016/0360-3016(92)90003-z.
Between 1962 and 1985, 371 patients had initial treatment for bulky endocervical carcinomas of the uterine cervix at The University of Texas M.D. Anderson Cancer Center. All patients had concentric expansion of the cervix by tumors that measured at least 6 cm in greatest transverse diameter. Of the 361 patients treated with curative intent, 211 (57%) had FIGO Stage I disease that was believed to be confined to the uterus, 59 (16%) had FIGO Stage IIA disease, and 101 patients (27%) had FIGO Stage IIB disease. Median follow-up time of surviving patients was 130 months. Actuarial survival rates of 361 patients treated with curative intent were 54% and 48% at 5 and 10 years, respectively. The actuarial pelvic disease control rate was 76% at 10 years. Patients whose tumors were less than 8 cm in maximum diameter (279 patients) had a better survival rate than those with tumors greater than or equal to 8 cm in diameter (92 patients) (p less than 0.01). Of the 282 patients who underwent lymphangiography, survival rate was significantly better for those with negative studies than it was for the 113 patients (40%) with positive or suspicious studies (p less than 0.01). There was no correlation between FIGO stage and survival rate (p = 0.64) or pelvic control rate (p = 0.59). Of patients treated with curative intent, treatment was by radiation alone (RT) in 244 (68%) or by radiation followed by hysterectomy (RT+S) in 117 (32%). Although there has been an overall shift in policy away from the use of adjuvant hysterectomy during the past decade, many patient selection factors also influenced the choice of treatment during the study years, resulting in a significantly higher proportion of patients with adverse prognostic features in the RT group. Patients chosen for treatment with RT alone had a greater likelihood of having tumors greater than or equal to 8 cm (p = 0.03), FIGO stage IIB (p less than 0.01), positive lymphangiogram (p = 0.02), and persistent palpable parametrial disease after external radiotherapy (p less than 0.01). Patients treated with RT alone also had a lower overall survival rate at 10 years than patients treated with RT+S (45% vs 64%, p less than 0.01). Although multivariate analysis suggested that treatment had an independent influence upon survival rate, it was difficult to draw firm conclusions about the value of adjuvant surgery because of the numerous biases in patient selection, some of which may have been difficult to quantify.(ABSTRACT TRUNCATED AT 400 WORDS)
1962年至1985年间,371例患有子宫颈巨大宫颈癌的患者在德克萨斯大学MD安德森癌症中心接受了初始治疗。所有患者的肿瘤均呈同心性扩展,最大横径至少为6厘米。在361例接受根治性治疗的患者中,211例(57%)为国际妇产科联盟(FIGO)I期疾病,认为局限于子宫;59例(16%)为FIGO IIA期疾病;101例(27%)为FIGO IIB期疾病。存活患者的中位随访时间为130个月。361例接受根治性治疗的患者的5年和10年精算生存率分别为54%和48%。10年时的精算盆腔疾病控制率为76%。肿瘤最大直径小于8厘米的患者(279例)的生存率高于肿瘤直径大于或等于8厘米的患者(92例)(p<0.01)。在282例行淋巴管造影的患者中,检查结果为阴性的患者的生存率明显高于113例(40%)检查结果为阳性或可疑的患者(p<0.01)。FIGO分期与生存率(p=0.64)或盆腔控制率(p=0.59)之间无相关性。在接受根治性治疗的患者中,244例(68%)仅接受放疗(RT),117例(32%)接受放疗后行子宫切除术(RT+S)。尽管在过去十年中总体政策已从使用辅助性子宫切除术转变,但在研究期间许多患者选择因素也影响了治疗选择,导致RT组中具有不良预后特征的患者比例明显更高。仅选择接受RT治疗的患者发生肿瘤大于或等于8厘米(p=0.03)、FIGO IIB期(p<0.01)、淋巴管造影阳性(p=0.02)以及体外放疗后可触及的宫旁组织疾病持续存在(p<0.01)的可能性更大。仅接受RT治疗的患者10年时的总生存率也低于接受RT+S治疗的患者(45%对64%,p<0.01)。尽管多因素分析表明治疗对生存率有独立影响,但由于患者选择存在众多偏差,其中一些可能难以量化,因此难以就辅助性手术的价值得出确凿结论。(摘要截取自400字)